Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy

M. Audrey Rudd, Dorinda George, Michael T. Johnstone, Richard T. Moore, Laura Collins, LeRoy E. Rabbani, Joseph Loscalzo

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

To evaluate the effect of thrombin on the dynamics of thrombolysis, we infused rabbits with heparin or hirudin alone or in conjunction with tissue-type plasminogen activator (t-PA) and monitored the kinetics of fibrinolysis and changes in ex vivo platelet aggregation responses over time. Both heparin and hirudin enhanced total fibrinolysis in an ex vivo arteriovenous shunt preparation: 82±2% and 79±2%, respectively, compared with 51±8% for t-PA alone (p<0.05) and 50±4% for t-PA plus aspirin (p<0.05). Heparin coadministered with t-PA significantly reduced the half-time for clot lysis compared with t-PA alone (p<0.05), whereas hirudin coadministered with t-PA significantly reduced the half-time for clot lysis compared with that for t-PA alone, t-PA plus aspirin, and t-PA plus heparin (5.5±0.6 versus 12.1±2.0 versus 12.6±2.2 versus 10.0±0.8 minutes, respectively; p<0.05). Both heparin and hirudin prevented the increase in ADP-induced platelet aggregation normally seen with t-PA alone (p<0.01 by t test; p<0.05 by two-way analysis of variance). These data demonstrate that selective, antithrombin III-independent thrombin inhibitors can enhance the efficacy of thrombolysis by modulating the dynamics of the process and preventing platelet activation associated with plasminogen activator therapy.

Original languageEnglish (US)
Pages (from-to)829-834
Number of pages6
JournalCirculation Research
Volume70
Issue number4
StatePublished - 1990

Fingerprint

Plasminogen Activators
Thrombolytic Therapy
Thrombin
Blood Platelets
Hirudins
Heparin
Fibrin Clot Lysis Time
Fibrinolysis
Platelet Aggregation
Aspirin
Antithrombin III
Platelet Activation
Tissue Plasminogen Activator
Adenosine Diphosphate
Analysis of Variance
Rabbits

Keywords

  • Heparin
  • Hirudin
  • Platelet aggregation
  • Thrombolysis

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Rudd, M. A., George, D., Johnstone, M. T., Moore, R. T., Collins, L., Rabbani, L. E., & Loscalzo, J. (1990). Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. Circulation Research, 70(4), 829-834.

Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. / Rudd, M. Audrey; George, Dorinda; Johnstone, Michael T.; Moore, Richard T.; Collins, Laura; Rabbani, LeRoy E.; Loscalzo, Joseph.

In: Circulation Research, Vol. 70, No. 4, 1990, p. 829-834.

Research output: Contribution to journalArticle

Rudd, MA, George, D, Johnstone, MT, Moore, RT, Collins, L, Rabbani, LE & Loscalzo, J 1990, 'Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy', Circulation Research, vol. 70, no. 4, pp. 829-834.
Rudd, M. Audrey ; George, Dorinda ; Johnstone, Michael T. ; Moore, Richard T. ; Collins, Laura ; Rabbani, LeRoy E. ; Loscalzo, Joseph. / Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. In: Circulation Research. 1990 ; Vol. 70, No. 4. pp. 829-834.
@article{f9aa3d939a2a44ce94b71d488fc1950e,
title = "Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy",
abstract = "To evaluate the effect of thrombin on the dynamics of thrombolysis, we infused rabbits with heparin or hirudin alone or in conjunction with tissue-type plasminogen activator (t-PA) and monitored the kinetics of fibrinolysis and changes in ex vivo platelet aggregation responses over time. Both heparin and hirudin enhanced total fibrinolysis in an ex vivo arteriovenous shunt preparation: 82±2{\%} and 79±2{\%}, respectively, compared with 51±8{\%} for t-PA alone (p<0.05) and 50±4{\%} for t-PA plus aspirin (p<0.05). Heparin coadministered with t-PA significantly reduced the half-time for clot lysis compared with t-PA alone (p<0.05), whereas hirudin coadministered with t-PA significantly reduced the half-time for clot lysis compared with that for t-PA alone, t-PA plus aspirin, and t-PA plus heparin (5.5±0.6 versus 12.1±2.0 versus 12.6±2.2 versus 10.0±0.8 minutes, respectively; p<0.05). Both heparin and hirudin prevented the increase in ADP-induced platelet aggregation normally seen with t-PA alone (p<0.01 by t test; p<0.05 by two-way analysis of variance). These data demonstrate that selective, antithrombin III-independent thrombin inhibitors can enhance the efficacy of thrombolysis by modulating the dynamics of the process and preventing platelet activation associated with plasminogen activator therapy.",
keywords = "Heparin, Hirudin, Platelet aggregation, Thrombolysis",
author = "Rudd, {M. Audrey} and Dorinda George and Johnstone, {Michael T.} and Moore, {Richard T.} and Laura Collins and Rabbani, {LeRoy E.} and Joseph Loscalzo",
year = "1990",
language = "English (US)",
volume = "70",
pages = "829--834",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy

AU - Rudd, M. Audrey

AU - George, Dorinda

AU - Johnstone, Michael T.

AU - Moore, Richard T.

AU - Collins, Laura

AU - Rabbani, LeRoy E.

AU - Loscalzo, Joseph

PY - 1990

Y1 - 1990

N2 - To evaluate the effect of thrombin on the dynamics of thrombolysis, we infused rabbits with heparin or hirudin alone or in conjunction with tissue-type plasminogen activator (t-PA) and monitored the kinetics of fibrinolysis and changes in ex vivo platelet aggregation responses over time. Both heparin and hirudin enhanced total fibrinolysis in an ex vivo arteriovenous shunt preparation: 82±2% and 79±2%, respectively, compared with 51±8% for t-PA alone (p<0.05) and 50±4% for t-PA plus aspirin (p<0.05). Heparin coadministered with t-PA significantly reduced the half-time for clot lysis compared with t-PA alone (p<0.05), whereas hirudin coadministered with t-PA significantly reduced the half-time for clot lysis compared with that for t-PA alone, t-PA plus aspirin, and t-PA plus heparin (5.5±0.6 versus 12.1±2.0 versus 12.6±2.2 versus 10.0±0.8 minutes, respectively; p<0.05). Both heparin and hirudin prevented the increase in ADP-induced platelet aggregation normally seen with t-PA alone (p<0.01 by t test; p<0.05 by two-way analysis of variance). These data demonstrate that selective, antithrombin III-independent thrombin inhibitors can enhance the efficacy of thrombolysis by modulating the dynamics of the process and preventing platelet activation associated with plasminogen activator therapy.

AB - To evaluate the effect of thrombin on the dynamics of thrombolysis, we infused rabbits with heparin or hirudin alone or in conjunction with tissue-type plasminogen activator (t-PA) and monitored the kinetics of fibrinolysis and changes in ex vivo platelet aggregation responses over time. Both heparin and hirudin enhanced total fibrinolysis in an ex vivo arteriovenous shunt preparation: 82±2% and 79±2%, respectively, compared with 51±8% for t-PA alone (p<0.05) and 50±4% for t-PA plus aspirin (p<0.05). Heparin coadministered with t-PA significantly reduced the half-time for clot lysis compared with t-PA alone (p<0.05), whereas hirudin coadministered with t-PA significantly reduced the half-time for clot lysis compared with that for t-PA alone, t-PA plus aspirin, and t-PA plus heparin (5.5±0.6 versus 12.1±2.0 versus 12.6±2.2 versus 10.0±0.8 minutes, respectively; p<0.05). Both heparin and hirudin prevented the increase in ADP-induced platelet aggregation normally seen with t-PA alone (p<0.01 by t test; p<0.05 by two-way analysis of variance). These data demonstrate that selective, antithrombin III-independent thrombin inhibitors can enhance the efficacy of thrombolysis by modulating the dynamics of the process and preventing platelet activation associated with plasminogen activator therapy.

KW - Heparin

KW - Hirudin

KW - Platelet aggregation

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=0026514409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026514409&partnerID=8YFLogxK

M3 - Article

C2 - 1551206

AN - SCOPUS:0026514409

VL - 70

SP - 829

EP - 834

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 4

ER -